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A large body of evidence links the presence of circulating
anti-Ro/SSA antibodies (anti-Ro/SSAs) in a mother with the
risk of her newborn developing neonatal lupus, a paradig-
matic model of transplacental passively acquired autoim-
munity whose main cardiac manifestation is congenital
complete atrioventricular block (congenital-III1AVB).1
Although the precise underlying mechanisms of the block
have not been fully elucidated, many experimental studies
have demonstrated the ability of anti-Ro/SSA to biochemi-
cally cross-react with L-type and T-type calcium channels
and thus signiﬁcantly inhibit the related currents, both of
which play a key role in the slow action potential of the
conduction system cardiomyocytes.2,3 This interaction, at
least in the initial acute phase, is electrophysiologically
reversible (spontaneously or after appropriate immunosup-
pressive treatment of the mother), and in some cases may
progress to an inﬂammatory-driven irreversible structural
damage of the conduction system (ie, the ﬁndings character-
izing the congenital-III1AVB).2,4
Anti-Ro/SSAs, including the anti-Ro/SSA-52kD and anti-
Ro/SSA-60kD subtypes, are frequently found in patientsKEYWORDS Isolated heart block in adults; Anti-Ro/SSA antibodies; Auto-
immunity; Immunosuppressive therapy; Calcium channels
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ELISA ¼ Enzyme-linked immunosorbent assay; FEIA ¼ Fluoroenzyme
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).with connective tissue diseases (CTDs), particularly in those
with Sjögren syndrome (30–95%) and systemic lupus
erythematosus (30–50%), but also in 0.5–2.7% of the healthy
population.4 Although it is believed that adult heart does not
represent an immunologic target for anti-Ro/SSA, increasing
data indicate that these autoantibodies may also affect the
adult conduction system, although to a lesser extent than the
fetal heart.5
Accordingly, we have recently proposed the existence of
2 possible forms of anti-Ro/SSA–associated atrioventricular
block (AVB) in adults: (1) a ﬁrst type resulting from an
immunomediated conduction-system interference secondary
to anti-Ro/SSA developed during adulthood (acquired form)
and (2) a second type representing the late progression of a
subclinical anti-Ro/SSA–induced congenital damage of the
conduction system (late-progressive congenital form).6
In the acquired form, characterized by the presence of anti-
Ro/SSAs in the affected subject, the conduction defect seems to
be related to a direct autoantibody-mediated inhibition of
calcium channels in cardiomyocytes, and their effect is poten-
tially reversible. Intrinsic age-related differences (lower calcium
channel reserve and underdeveloped sarcoplasmic reticulum in
the fetal heart)4 may explain why anti-Ro/SSAs induce only an
electrophysiological effect in adults, without evolving to an
inﬂammatory-driven heart injury as in newborns.6 However, a
prenatally established structural (and irreversible) damage of
immune origin appears to be the pathologic basis of the late-
progressive congenital form, with a subsequent autoantibody-
independent worsening with age. Accordingly, in late progres-
sive congenital form patients anti-Ro/SSAs are not detectable,
despite the seropositivity of their mothers. Thus, a recovery
potential of the immunosuppressive therapy is expected in the
acquired form only. Preliminary data indicate a rapid recovery of
the conduction defects in patients with acquired anti-Ro/SSA–
associated AVB after administration of immunosuppressivepen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.03.019
KEY TEACHING POINTS
 Congenital atrioventricular block (AVB) is the most
recognized consequence of the transplacental
passage of anti-Ro/SSA antibodies from the mother
to the fetus. Although traditionally considered
invulnerable, the adult conduction system also may
represent a target for these antibodies.
 Recent data suggest 2 possible forms of anti-Ro/
SSA–associated AVB in adults: (1) an acquired form,
resulting from a direct and reversible
autoantibody-mediated electrophysiological
inhibition of cardiomyocyte calcium channels, and
(2) a late-progressive congenital form related to a
subclinical, prenatally established structural
damage induced by maternally acquired anti-Ro/
SSAs, with a subsequent autoantibody-
independent worsening with age until a diagnosis
in the patient’s adulthood. Nevertheless, in some
patients both the pathogenic mechanisms are
concomitantly involved (mixed form).
 Whereas in the acquired form the patient shows
circulating anti-Ro/SSAs, only the patient’s mother
is seropositive in the late-progressive congenital
form. Thus, a recovery potential of
immunosuppressive therapy is expected in the
acquired form only.
 In adults with unexplained AVB, even in the
absence of signs of connective tissue disease, a
speciﬁc anti-Ro/SSA testing (enzyme-linked
immunosorbent assay þ Western blot) in the
patient and patient’s mother may be of diagnostic
value. If anti-Ro/SSAs are detected in the patient,
immunomodulating therapy may induce a rapid
AVB recovery, thus avoiding or delaying pacemaker
implantation.
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underlying these 2 forms is reported elsewhere.6
The epidemiologic impact of anti-Ro/SSA–associated
AVB in adults is higher than expected, probably because
these patients (and their mothers) are frequently asympto-
matic for CTDs and are therefore difﬁcult to identify. In fact,
available retrospective population studies indicate that the 2
forms, globally considered, may represent at least 20% of all
cases of isolated III1AVB of unknown origin in adults
(approximately 10% of cases attributed to each form).7,8
Thus, the importance of considering the possibility of anti-
Ro/SSA–associated AVB and speciﬁcally testing for anti-
Ro/SSAs in patients with “idiopathic” AVB should be
emphasized, particularly for the important beneﬁts comingfrom an early immunosuppressive treatment of the acquired
form.6
The clinical cases reported here provide further evidence
in support of this view and demonstrate how in some patients
both the pathogenic mechanisms characterizing the 2 forms
of adult-onset anti-Ro/SSA–associated AVB may be con-
comitantly involved (mixed form).Case reports
Case 1
A 29-year-old woman presented with chest pain, faintness,
paleness, and sweating that had occurred acutely in the past
few hours. An electrocardiogram (ECG) recorded at the
emergency department demonstrated III1AVB and wide
QRS ventricular escape rhythm with a rate of approximately
30–40 beats per minute (bpm), suggesting a conduction
impairment distal to the bundle of His (Figure 1A). The
clinical history of the patient was negative for relevant
factors except for autoimmune thyroiditis, which was being
treated with thyroxine, and subclinical positivity for anti-Ro/
SSAs (no sign of CTDs) that had been incidentally detected 3
years before. As such, the patient had been carefully
monitored for the risk of neonatal lupus during 2 previous
pregnancies that delivered 2 healthy babies. Table 1
The patient was admitted to the intensive cardiac care
unit. Laboratory investigation did not show abnormalities in
thyroid hormone or thyrotropin levels. As expected, anti-
nuclear antibody (ANA) testing results were positive
(1:1280, speckled pattern), with very high circulating levels
of anti-Ro/SSAs, including both anti-Ro/SSA-52kD and
anti-Ro/SSA-60kD subspeciﬁcities, as assessed by an immu-
noenzymatic enzyme-linked immunosorbent assay (ELISA)
method (4240 U/mL, reference values o7; ﬂuoroenzyme
immunoassay [FEIA] by a Phadia EliA system [Thermo
Fisher Scientiﬁc, Waltham, MA]). The presence of the anti-
Ro/SSA-52kD subspeciﬁcity was conﬁrmed by Western
blot analysis (MarDx Marblot HEp-2; Trinity Biotech,
Carlsbad, CA).
Transthoracic and transoesophageal echocardiography
were performed, and both excluded signiﬁcant structural heart
abnormalities. The patient was closely monitored for the
following 12 hours, and then a permanent pacemaker was
implanted (Figure 2B) to address the persistence of sympto-
matic III1AVB. The day after, and in consultation with the
patient’s immunologist (A.B.), immunosuppressive therapy
with corticosteroids 1 mg/kg/d was started (intravenous
methylprednisolone for the ﬁrst day, and then oral predni-
sone). During the second day of treatment, III1AVB disap-
peared and a normal AV conduction was present. The patient
was discharged, and a short-time follow-up ECG approx-
imately 2 weeks later conﬁrmed the persistence of a normal
AV conduction (Figure 2C). However, in consideration of the
fact that a pacemaker had already been implanted and the
patient was totally asymptomatic for rheumatologic manifes-
tations, corticosteroids were progressively tapered until com-
plete termination to avoid unjustiﬁed side effects. A further
Figure 1 Resting electrocardiograms of case 1. A: At hospital admission, the recording shows third-degree atrioventricular block. B: After pacemaker
implantation. C: 2 weeks after immunosuppressive therapy with prednisone, the recording showed normal atrioventricular conduction.
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rhythm driven by pacemaker stimulation. Notably, clinical
and instrumental monitoring in the following years did not
show the appearance of possibly concealed sarcoidosis or
other inﬂammatory/inﬁltrative cardiac diseases, despite per-
sistent interruption of immunosuppressive therapy.Case 2
An I1AVB (PR interval 320 milliseconds) was demonstrated
in an asymptomatic 23-year-old woman who underwent a
routine screening ECG in the course of a preemployment
visit (Figure 2A). The following 24-hour ambulatory ECG
showed intermittent II1AVB and episodes of high-gradeTable 1 Patient characteristics by case
Case Gender
Age,
y
AV block
degree
Connective tissue disease Anti-Ro/SSA a
Patient Mother
Patient
FEIA WB
1 ♀ 29 third-degree No No anti-52kD
anti-60kD
an
2 ♀ 23 high-grade No No — —
3 ♀ 21 high-grade No No — an
AV ¼ atrioventricular; FEIA ¼ ﬂuoroenzyme immunoassay; WB ¼ Western bloAVB with wide QRS escape beats (Figure 2B). The block
appeared more likely to be at the AV nodal level, because of
the narrow QRS complexes when conducted. The patient’s
clinical history was negative for any relevant disease. The
retrospective analysis of a previous ECG performed at
9 years of age demonstrated that I1AVB was already present
at that time. The patient was not taking any drugs, and there
was no instrumental evidence of structural heart disease.
Laboratory data, including thyroid hormone levels, were
normal. The patient was speciﬁcally tested for ANA and anti-
Ro/SSAs, and results of both tests were negative. However,
the results of the same tests were positive in the patient’s
mother, a 51-year-old woman who was otherwise healthy
except for a euthyroid multinodular goiter, under thyroidntibodies
Response to
immunosuppressive
therapy Form
Mother
FEIA WB
ti-52kD NA NA Yes Acquired
anti-60kD anti-52kD Not evaluated Late-progressive
congenital
ti-52kD — anti-52kD Yes Mixed
t; NA ¼ not available; (-) ¼ negative.
Figure 2 Electrocardiograms (ECGs) of case 2. A: Resting ECG showed ﬁrst-degree atrioventricular block (PR interval, 320 milliseconds). B: A 24-hour
ambulatory ECG showed intermittent second-degree atrioventricular block and episodes of high-grade atrioventricular block with wide QRS escape beats.
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Indeed, FEIA displayed high levels of anti-Ro/SSAs (128
U/mL), with positivity for anti-Ro/SSA-60kD. Moreover,
Western blot results revealed the presence of the subspeci-
ﬁcity anti-Ro/SSA-52kD.
The patient underwent close clinical and electrocardio-
graphic follow-up in the next months, until episodes of
dizziness led to the insertion of a backup permanent
pacemaker.
Case 3
A 21-year-old woman presented with asymptomatic high-
grade AVB, incidentally diagnosed during an endocrinology
medical examination. ECG at rest showed III1AVB, narrow
QRS, and a ventricular rate of approximately 45 bpm
(Figure 3A). A 24-hour ambulatory ECG conﬁrmed the
presence of high-grade AVB for the most part of the day,
with episodes of II1AVB (Mobitz type 1–2).
The patient had a history of autoimmune thyroiditis,
which was being treated with thyroxine. A subclinical
positivity for autoantibodies to gastric parietal cells was alsoreported. Family history was negative for heart disease or
autoimmune disorders. The patient had no history of cardiac
surgery, ablation procedures, or drug use. There was no
evidence of inﬁltrative heart diseases or myocardial ische-
mia. Transthoracic echocardiography and cardiac magnetic
resonance imaging were unremarkable. No clinical manifes-
tations of rheumatologic disease were present. Levels of
thyrotropin were normal. Laboratory evaluation demon-
strated a positive test for anti-Ro/SSA-52kD (Western blot),
although FEIA testing was negative. Despite the patient’s
negative history for conduction disturbances, a retrospective
evaluation of available previous ECGs (recorded at ages 7
and 15) revealed the presence of a previously unrecognized
I1AVB (PR interval 240 milliseconds) (Figure 4).
Laboratory testing of the mother, who was asymptomatic
for CTDs, showed a positive result for ANA at a titer of
1:320, with a homogeneous pattern (ie, diffuse nuclear
ﬂuorescence), and anti-Ro/SSA-52kD (Western blot). Also
in this case, FEIA results were negative.
Intravenous methylprednisolone was started for the patient
at an immunosuppressive dose of 1 mg/kg/d, resulting in a
Figure 3 Resting electrocardiograms (ECGs) of case 3.A:At baseline, the ECG showed high-grade atrioventricular block. B: 5 days after the onset of the ﬁrst
course of intravenous methylprednisolone, the ECG showed ﬁrst-degree atrioventricular block. C: 2 months after discontinuation of oral immunosuppressive
therapy with azathioprine and prednisone, the ECG showed high-grade atrioventricular block; the patient was symptomatic. D: After the second course of
intravenous methylprednisolone: ﬁrst-degree atrioventricular block; the patient became asymptomatic.
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ﬁndings(disappearance of high-grade AVB; presence of
I1AVB) (Figures 3B and Figure 4). Maintenance oral immu-
nosuppressive therapy with azathioprine (100 mg daily) and
prednisone (progressively reduced to 6.25 mg daily) was
started. After 1, 3, and 6 months, new 24-hour ambulatory
ECGs conﬁrmed the absence of high-grade AVB, and the
persistence of I1AVB (although with phases of II1AVB,
Mobitz type 1–2) (Figure 4). At this time (3 months), Western
blot results were negative for anti-Ro/SSA-52kD. However,
since the patient was persistently asymptomatic and reluctant
to long-term immunosuppressive therapy, the treatment was
stopped. 2 months later, the patient presented persistent
presyncopal symptoms, particularly in standing or sitting
positions. Electrocardiogram demonstrated the reoccurrence
of high-grade AVB with marked bradycardia (approxi-
mately 35 bpm) (Figure 3C). Administration of intravenous
methylprednisolone again rapidly improved the conduction
disturbances: soon the patient become completely asympto-
matic and ECG tracings showed I1AVBwith a mean heart rateof 50–60 bpm (Figure 3D). A new immuno-Western blot
performed at that time revealed the reappearance of anti-Ro/
SSA-52kD positivity. The patient again underwent cardiac
magnetic resonance imaging, and in this instance no signs of
inﬁltrative or inﬂammatory diseases, particularly sarcoidosis,
were detected. Currently, 1 month after restarting combined
therapy with azathioprine and prednisone, the patient is stably
asymptomatic and ECG shows I1AVB (with phases of
II1AVB revealed by 24-hour ambulatory ECG) (Figure 4).
The possibility of implanting a pacemaker is still under
consideration.Discussion
The cases reported in this paper illustrate the different forms
of anti-Ro/SSA–associated AVB that can be observed in
adults.
The ﬁrst patient represents an acquired form, as indica-
ted by circulating anti-Ro/SSAs. The pathogenic relevance
of these autoantibodies in AVB development is strongly
Figure 4 The time course of clinical, electrocardiographic, and laboratory changes, and immunosuppressive therapy in case 3. Gray: Data obtained from a
retrospective evaluation of the patient and the patient’s mother. Yellow: Data obtained from the prospective evaluation of patient. Hi1AVB ¼ high-grade
atrioventricular block.
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disturbance soon after the onset of the steroid treatment.
Conversely, the detection of anti-Ro/SSAs in the mother, but
not in the patient, as well as the demonstration of signs of
subclinical conduction system damage already present at the
childhood stage (I1AVB at 9 years of age), identify the
second case as a late-progressive congenital form.
Finally, in our opinion, the third case may represent a
mixed form, in which both the mechanisms are involved.
Indeed, the data suggest that, in this case, a peculiar “2-hits”
autoimmune conduction system damage has developed. The
ﬁrst “hit” was the result of the transplacental passage of anti-
Ro/SSAs that may have induced a subclinical congenital
injury of the conduction system (incomplete AVB). The
following development of a multiorgan autoimmune res-
ponse, including anti-Ro/SSAs, during the postnatal life
may have represented the second “hit” leading to the
progression of the defect to high-grade AVB. Interestingly,
another case of an anti-Ro/SSA–positive congenital-
III1AVB (diagnosed as such at birth) followed by the
development of anti-Ro/SSA in adult life has been already
described,9 thus conﬁrming the existence of this possibility
as a probable result of the transmission of a “geneticpredisposition” to autoimmune response. The regression to
incomplete AVB after immunosuppressive therapy in this
patient further conﬁrms that adult-onset anti-Ro/SSA–asso-
ciated damage is reversible, whereas the fetal injury is
permanent.
Noteworthy, in all the above-depicted cases, the presence
of anti-Ro/SSA with pathogenic effects on the heart was not
associated with clinical signs of autoimmune disease. In fact,
patients 1 and 3 and the anti-Ro/SSA–positive mothers of
patients 2 and 3 were totally asymptomatic. Although
patients 1 and 3 had been previously diagnosed with auto-
immune thyroiditis, they did not have clinical manifestations
of CTD. This fact (in agreement with previous reports of
anti-Ro/SSA–associated life-threatening rhythm disturban-
ces in adult patients10,11), with the evidence that anti-Ro/
SSA–positive subjects in the general population are fre-
quently asymptomatic for AD,12 emphasizes the concept that
in most cases only speciﬁc testing may reveal an anti-Ro/
SSA–associated mechanism of disease in adult patients with
isolated AVB of unknown origin.
The level of the block in these patients represents another
intriguing issue. Indeed, whereas in children with congenital
AVB it is generally localized at the AV node,13 our and
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(particularly in the acquired form) the level of block may be
more frequently distal to the bundle of His. It is currently
unclear whether this feature is dependent on age-related differ-
ences in calcium channel density at the AV node vs the His-
Purkinje system, and whether an electrophysiological study
may provide useful diagnostic and prognostic information.
Finally, our report (particularly case 3) also suggests that
an ELISA method alone is probably not able to detect all
patients with anti-Ro/SSA–associated AVB, underscoring
the crucial importance of completing anti-Ro/SSA testing
using Western blot analysis in all patients whose ELISA
results are negative. Further support of this view, also
substantiated by previous data demonstrating a higher
sensibility of Western blot in detecting anti-Ro/SSA-52kD
with respect to immunoenzymatic methods,14 another case
of anti-Ro/SSA-52kD–positive (blot only) III1AVB fully
reversing after immunosuppressive therapy(acquired form)
has been recently described.10References
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